MARKET

ALEC

ALEC

Alector
NASDAQ
1.390
-0.030
-2.11%
After Hours: 1.386 -0.005 -0.32% 16:29 12/16 EST
OPEN
1.390
PREV CLOSE
1.420
HIGH
1.450
LOW
1.350
VOLUME
853.63K
TURNOVER
--
52 WEEK HIGH
3.400
52 WEEK LOW
0.8700
MARKET CAP
151.72M
P/E (TTM)
-1.2987
1D
5D
1M
3M
1Y
5Y
1D
Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst
Seeking Alpha · 8h ago
Analysts Offer Insights on Healthcare Companies: Alector (ALEC) and Novan (NOVN)
TipRanks · 1d ago
Weekly Report: what happened at ALEC last week (1208-1212)?
Weekly Report · 1d ago
Alector Appoints Neil Berkley as CFO
TipRanks · 4d ago
Alector Names Interim CFO Berkley to Role on Permanent Basis
Dow Jones · 4d ago
Alector names Neil Berkley as CFO, Chief Business Officer
TipRanks · 4d ago
Alector Names Neil Berkley as Chief Financial Officer and Chief Business Officer
Reuters · 4d ago
Press Release: Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Dow Jones · 4d ago
More
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Webull offers Alector Inc stock information, including NASDAQ: ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.